Upcoming Presentations Related to the Lutonix Drug-Coated Balloon LEVANT 2 Trial
Upcoming Presentations Related to the Lutonix Drug-Coated Balloon LEVANT 2 Trial
MURRAY HILL, N.J.--(BUSINESS WIRE)-- C. R. Bard, Inc. (NYS: BCR) today announced two upcoming presentations related to the company's Lutonix Drug-Coated Balloon (DCB) LEVANT 2 Trial.
The first presentation will be at the Vascular Interventional Advances (VIVA) meeting in Las Vegas, Nevada on October 10, 2013. In this presentation, Professor Dierk Scheinert, M.D., Head of the Department of Medicine, Angiology and Cardiology, Park-Krankenhaus Hospital, Leipzig, Germany and LEVANT 2 Co-Primary Investigator, is expected to present information related to the study design and early results from patients who were treated with the Lutonix DCB prior to the beginning of randomization of the trial, otherwise known as roll-in patients.
The second presentation will be at the Transcatheter Cardiovascular Therapies (TCT) conference in San Francisco, California on October 30, 2013. In this presentation, Kenneth Rosenfield, M.D., Section Head for Vascular Medicine and Intervention, Massachusetts General Hospital and LEVANT 2 Co-Primary Investigator, is expected to present information related to the demographics and six-month follow-up results from the patients randomized in the LEVANT 2 trial.
C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.
The data provided in the above-mentioned presentations should not be construed as representative of the ultimate outcome of the LEVANT 2 trial or seen as an indication of the trial meeting its primary endpoints or as an indication of the likelihood of the product gaining regulatory approval or being successful commercially. This press release contains some forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations. The accuracy of these statements is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as "anticipate," "estimate," "expect," "project," "intend," "forecast," "plan," "believe" and other words of similar meaning. Many factors may cause actual results to differ materially from anticipated results, including product development, sales efforts, the outcome of contingencies such as legal proceedings, and other economic, business competitive and regulatory factors. Please refer to the Cautionary Statement regarding forward-looking information in Bard's June 30, 2013 10-Q and the information under the caption "risk factors" in the company's 2012 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.
C. R. Bard, Inc.
Investor Relations:
Todd W. Garner, 908-277-8065
Vice President, Investor Relations
or
Media Relations:
Scott T. Lowry, 908-277-8365
Vice President and Treasurer
KEYWORDS: United States North America California Nevada New Jersey
INDUSTRY KEYWORDS:
The article Upcoming Presentations Related to the Lutonix Drug-Coated Balloon LEVANT 2 Trial originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
